


Northern Lincolnshire Area Prescribing Committee





Northern Lincolnshire Area Prescribing Committee

Box A: Lubiprostone NICE TA318

Lubiprostone is recommended as an option for treating chronic idiopathic constipation, that is, for adults in whom treatment with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at **least 6 months**, has failed to provide adequate relief and for whom invasive treatment for constipation is being considered.

If no effective response after 2 weeks treatment, the patient should be re-examined and the benefit of continuing treatment reconsidered.

Lubiprostone should only be prescribed by a clinician with experience of treating chronic idiopathic constipation, who has carefully reviewed the patient's previous courses of laxative treatments.

Dietary and lifestyle

Increase fibre and fluid intake

Increase activity and exercise

Regular unhurried toilet

Responding to defaecation

Source of diet information: Food Fact Sheets on Fibre and

Fruit and vegetables Public Health England's

routine

urge

Box B: Naloxegol <u>NICE TA345</u>

Naloxegol is indicated, as an option, for the treatment of opioid-induced constipation in adult when the constipation is not adequately responding to laxatives.

An inadequate response is defined as opioid-induced constipation symptoms of at least moderate severity in at least 1 of the 4 stool symptom domains while taking at least 1 class of laxative for at least 4 days during the prior 2 weeks.

The four stool symptoms domain are: incomplete bowel movement, hard stools, straining or false alarms.

Starting dose is 25mg daily (renal impairment: start at 12.5mg daily), see BNF and <u>SPC</u>

Stop all maintenance laxative treatments.

If no adequate response, refer to specialist.

Box C – Red flags/Warning signs Unexplained weight loss Unexplained abdominal pain Unexplained rectal bleeding Iron deficiency anaemia Tenesmus Family history of bower cancer or inflammatory bowel disease Test positive for faecal occult blood See NICE <u>NG12</u>

Colour code:

Green: GP initiating and monitoring Amber: Specialist initiation with GP continuation. Red: Specialist Treatment

booklet The Eatwell Guide



Northern Lincolnshire Area Prescribing Committee

Prucalopride Pathway

Prucalopride can be used for the treatment of chronic constipation in women in whom laxatives have not produced adequate response

At least two laxatives from different classes, at the highest tolerated recommended doses for at least 6 months

No adequate response

Initiate Prucalopride (specialist only). Patient remains under specialist care. A review takes place at 4 weeks and continued if appropriate for a further 4 weeks

After the initial 8 weeks treatment, prescribing is continued in primary care by GP if adequate response to Prucalopride

If good response

6 months review by specialist at OPD

If no /inadequate response

If good response

Prescribing continued by GP for a further 6 months

Invasive management (stoma/sacral neuromodulation/biofeedback) – see Management of Constipation Flowchart

If no/inadequate response, refer to specialist

Prucalopride is for use in only women NICE TA211.


Prucalopride has now been <u>licensed</u> for use in men and women. NICE has not updated its guidance for use in men.

If not effective after 4 weeks, the patient should be re-examined and benefit of treatment continuation reviewed.



Northern Lincolnshire Area Prescribing Committee

IBS-C Pathway with Linaclotide





References:

GPonline. Constipation. [online] Available at: <<u>http://www.gponline.com/red-flag-symptoms-constipation/gi-tract/article/880832</u>> [Accessed 20 October 2017].

NICE Clinical Knowledge Summaries. Constipation. [online] Available at: <<u>https://cks.nice.org.uk/constipation</u>> [Accessed 19 October 2017].

NICE, 2010. Technology appraisal guidance [TA211]: Prucalopride for the treatment of chronic constipation in women. [online] Available at < <u>https://www.nice.org.uk/Guidance/TA211</u>> [Accessed 19 October 2017].

NICE, 2014. Technology appraisal guidance [TA318]: Lubiprostone for treating chronic idiopathic constipation. [online] Avaialable at < <u>https://www.nice.org.uk/guidance/ta318</u>> [Accessed 25 October 2017].

NICE, 2015. Technology appraisal guidance [TA345]: Naloxegol for treating opioid-induced constipation. [online] Available at <<u>https://www.nice.org.uk/guidance/ta345</u>> [Accessed 20 October 2017].

NICE, 2017. Clinical guideline [CG61]: Irritable bowel syndrome in adults: diagnosis and management. [online] Available at < <u>https://www.nice.org.uk/guidance/cg61</u>> [Accessed 30 October 2017].

NICE, 2017. NICE guideline [NG12]: Suspected cancer: recognition and referral. [online] Available at <<u>https://www.nice.org.uk/guidance/ng12</u>> [Accessed 29 October 2017].